Sandoz Group AG

History

Year	Detail
1886	Edouard Sandoz and Alfred Kern established Kern & Sandoz to manufacture and sell synthetic dyes in Basel, Switzerland.
1929	The company launched Calcium Sandoz, one of the highest-selling pharmaceutical products for preventing and treating calcium deficiency.
1939	Kern & Sandoz was renamed Sandoz Ltd. and operated for approximately sixty years.
1980	Sandoz developed interferon alfa, one of its first recombinant proteins, which is used for various therapies, such as vaccines, hormones, and enzymes.
1996	Sandoz merged with Ciba-Geigy, which led to the development of Novartis. Both companies continued their activities independently till 1996.
2015	The company's Zarxio (filgrastim) became the first biosimilar to be granted marketing authorization in the U.S. It is used to treat neutropenia associated with chemotherapy.
2022	Novartis separated its generics and biosimilars division of Sandoz to create a standalone company by way of a 100% spin-off.
2023	Sandoz became an independent company and was established in Switzerland. The company also aims to be listed on the SIX Swiss Exchange and has an American Depositary Receipt (ADR) program in the U.S.